EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA’s “Study May Proceed” letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the first patient to be dosed in the first ...
See Details: EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder